Cargando…

Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning

BACKGROUND: Different protocols have been suggested to treat aluminum phosphide (ALP) poisoning. We aimed to evaluate the possible therapeutic effect of hyperinsulinemia/euglycemia (HIE) in treatment of ALP poisoning. METHODS: In a prospective interventional study, a total of 88 ALP-poisoned patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassanian-Moghaddam, Hossein, Zamani, Nasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979794/
https://www.ncbi.nlm.nih.gov/pubmed/27495040
http://dx.doi.org/10.1097/MD.0000000000004349
_version_ 1782447376641818624
author Hassanian-Moghaddam, Hossein
Zamani, Nasim
author_facet Hassanian-Moghaddam, Hossein
Zamani, Nasim
author_sort Hassanian-Moghaddam, Hossein
collection PubMed
description BACKGROUND: Different protocols have been suggested to treat aluminum phosphide (ALP) poisoning. We aimed to evaluate the possible therapeutic effect of hyperinsulinemia/euglycemia (HIE) in treatment of ALP poisoning. METHODS: In a prospective interventional study, a total of 88 ALP-poisoned patients were included and assigned into HIE group undergoing glucose/insulin/potassium (GIK) protocol and a control group that was managed by routine conventional treatments. The 2 groups were then compared regarding the signs and symptoms of toxicity and their progression, development of complications, and final outcome to detect the possible effect of GIK protocol on the patients’ course of toxicity and outcome. RESULTS: The 2 groups were similar in terms of demographic characteristics and on-arrival vital signs and lab tests. Using GIK protocol resulted in significantly longer hospital stays (24 vs 60 hours; P < 0.001) and better outcomes (72.7% vs 50% mortality; P = 0.03). Regression analysis showed that GIK duration was an independent variable that could prognosticate mortality (odds ratio [95% confidence interval] = 1.045 [1.004,1.087]). The risk of mortality decreased by 4.5% each hour after initiation of GIK. CONCLUSION: GIK protocol improves the outcome of ALP poisoning and increases the length of hospital stay.
format Online
Article
Text
id pubmed-4979794
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49797942016-08-18 Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning Hassanian-Moghaddam, Hossein Zamani, Nasim Medicine (Baltimore) 3900 BACKGROUND: Different protocols have been suggested to treat aluminum phosphide (ALP) poisoning. We aimed to evaluate the possible therapeutic effect of hyperinsulinemia/euglycemia (HIE) in treatment of ALP poisoning. METHODS: In a prospective interventional study, a total of 88 ALP-poisoned patients were included and assigned into HIE group undergoing glucose/insulin/potassium (GIK) protocol and a control group that was managed by routine conventional treatments. The 2 groups were then compared regarding the signs and symptoms of toxicity and their progression, development of complications, and final outcome to detect the possible effect of GIK protocol on the patients’ course of toxicity and outcome. RESULTS: The 2 groups were similar in terms of demographic characteristics and on-arrival vital signs and lab tests. Using GIK protocol resulted in significantly longer hospital stays (24 vs 60 hours; P < 0.001) and better outcomes (72.7% vs 50% mortality; P = 0.03). Regression analysis showed that GIK duration was an independent variable that could prognosticate mortality (odds ratio [95% confidence interval] = 1.045 [1.004,1.087]). The risk of mortality decreased by 4.5% each hour after initiation of GIK. CONCLUSION: GIK protocol improves the outcome of ALP poisoning and increases the length of hospital stay. Wolters Kluwer Health 2016-08-07 /pmc/articles/PMC4979794/ /pubmed/27495040 http://dx.doi.org/10.1097/MD.0000000000004349 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3900
Hassanian-Moghaddam, Hossein
Zamani, Nasim
Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
title Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
title_full Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
title_fullStr Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
title_full_unstemmed Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
title_short Therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
title_sort therapeutic role of hyperinsulinemia/euglycemia in aluminum phosphide poisoning
topic 3900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979794/
https://www.ncbi.nlm.nih.gov/pubmed/27495040
http://dx.doi.org/10.1097/MD.0000000000004349
work_keys_str_mv AT hassanianmoghaddamhossein therapeuticroleofhyperinsulinemiaeuglycemiainaluminumphosphidepoisoning
AT zamaninasim therapeuticroleofhyperinsulinemiaeuglycemiainaluminumphosphidepoisoning